Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes
Graefe's Archive for Clinical and Experimental Ophthalmology · 2024
DOI: 10.1007/s00417-024-06529-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von İffet Merve Uçar Baytaroğlu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Uşak Training and Research Hospital, Uşak, Turkey. ucarmerve1988@hotmail.com. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetes Mellitus, Type 2, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Usak University.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
This study aimed to evaluate the impact of anti-TNF (biological) therapies on the incidence and progression of diabetic retinopathy. Materials and methods A cross-sectional analysis of 50 diabetic patients with rheumatic diseases (group 1) was performed. An age-, sex-, and HbA1c-matched control group (group 2) was formed from a pool of diabetic patients who underwent regular eye examinations. The presence or absence of diabetic retinopathy was also assessed. Comorbidities such as hypertension, coronary artery disease, and hyperlipidemia were also evaluated as possible confounding factors.
Results
Hundred eyes of 50 patients were evaluated in each group. Only three patients in group 1 had non-proliferative retinopathy. The median duration of rheumatic disease was 9 years, whereas that of diabetes was 11 years. The mean duration of anti-TNF therapy was 4 years. In the control group of diabetes-only patients, 13 patients developed some form of newly diagnosed diabetic retinopathy during the last five years. The calculated retinopathy occurrence between the groups was statistically significant ( p < 0.05). In this study, the incidence rate ratio for patients receiving anti-TNF treatment was calculated as 0.4 in the study.
Conclusion
TNF inhibitors, with their anti-inflammatory effects, positively impact diabetic complications by reducing the incidence of retinopathy. To our knowledge, this is the first study to evaluate retinopathy development after anti-TNF therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Department, Uşak Training and Research Hospital, Uşak, Turkey. ucarmerve1988@hotmail.com.
- Ophthalmology Department, Uşak Training and Research Hospital, Uşak, Turkey.
- Endocrinology Department, Uşak Training and Research Hospital, Uşak, Turkey.
ORCID-Profile: Ata Baytaroğlu, Merve Uçar Toros, Hatice Daldal
Förderung
- Usak University
Zitieren
APA
Baytaroğlu, İ. M. U., Baytaroğlu, A., Toros, M. U., & Daldal, H. (2024). Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06529-3
Vancouver
Baytaroğlu İMU, Baytaroğlu A, Toros MU, Daldal H. Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06529-3
BibTeX
@article{Baytarolu2024,
author = {Baytaroğlu, İffet Merve Uçar and Baytaroğlu, Ata and Toros, Merve Uçar and Daldal, Hatice},
title = {Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2024},
doi = {10.1007/s00417-024-06529-3}
}
EUVIMED